###begin article-title 0
Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease
###end article-title 0
###begin p 1
Recommended by Jan van Amsterdam
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 397 399 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 474 476 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 484 490 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P:.011</italic>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson's disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3 +/- 0.4 mumol/L) was significantly lower than that in the control group (2.8 +/- 0.6 mumol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results.
###end p 3
###begin title 4
1. Introduction
###end title 4
###begin p 5
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
Parkinson's disease (PD) is a common neurodegenerative disorder that can cause significant disability and decline in the quality of life. It is not a single entity simply resulting from a dopaminergic deficit, rather most likely caused by a combination of genetic predisposition and environmental factors. Mitochondrial dysfunction has been proposed as a general basic mechanism underlying the neurodegeneration seen in PD [1, 2]. This condition is related to increased free radical production, oxidative stress, and decreased ATP production, that leads to increased intracellular calcium concentration, excitotoxicity, and nitric oxide related cellular damage [1, 3, 4].
###end p 5
###begin p 6
###xml 243 244 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 940 941 940 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 942 943 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1092 1093 1092 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 872 878 <span type="species:ncbi:9606">people</span>
Nitric oxide (NO) has varied physiological roles in the nervous system, including morphogenesis and developmental synaptic plasticity. However, in the pathological conditions, it could contribute to the oxidative stress and neurodegeneration [4, 5]. Clinical findings, evidences from experimental models, and postmortem studies revealed a connection of NO with the selective degeneration of dopaminergic neurons in the PD [4, 6]. Formation of NO can be regulated via the GH-IGF-1 system, but the cellular mechanism for this regulation is unknown [7]. Growth hormone (GH) exerts much of its biological activity by stimulating the production of (IGF-1), which is synthesized in nearly every tissue including the central nervous system. Insulin and IGF-1 have metabolic, neurotrophic, neuromodulatory, and neuroendocrine important functions in the brain. Studies among older people suggest that the GH-IGF-1 axis activity is reduced with age [7-9]. Thus, IGF-1 deficiency may be involved in the pathogenesis of age-related neurodegenerative diseases and might be relevant to the etiology of PD [8-10].
###end p 6
###begin p 7
###xml 177 185 <span type="species:ncbi:9606">patients</span>
To further reveal the pathophysiological processes that were seen in the PD, we aimed to investigate the role of circulating GH, IGF-1, IGFBP-3, and NO concentrations in the PD patients in comparison with healthy subjects.
###end p 7
###begin title 8
2. Materials and Methods
###end title 8
###begin p 9
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 98 105 <span type="species:ncbi:9606">patient</span>
###xml 266 273 <span type="species:ncbi:9606">patient</span>
###xml 288 295 <span type="species:ncbi:9606">patient</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">Patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
###xml 872 880 <span type="species:ncbi:9606">patients</span>
After receiving approval from the Hospital's Ethics Committee, we recruited patients from the out-patient clinic of our Neurology Department. All subjects had signed written informed consent before participation. A neurologist performed physical examination of each patient and noted the patient history. All PD patients showed rest tremor, rigidity, bradykinesia, and postural instability. These features with any one had begun displayed asymmetry. Patients with Parkinsonism, stroke, and dementia were excluded from the study. The patients with PD and healthy control groups were consisted of nonsmokers without other neurodegenerative, chronic, or infectious diseases. There were 25 patients in the PD group and 25 matched healthy subjects in the control group. The revision of Hoehn and Yahr staging scale was used to estimate the disease severity [11]. All of the PD patients were under the treatment with anti-PD drugs.
###end p 9
###begin p 10
###xml 501 503 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Venous blood samples were collected at 8 AM and 9 AM after an overnight fasting period. Within 1 hour after blood taking, the blood was centrifuged at 4000 rpm for 10 minutes, and the serum was stored at -70degreesC until analyzed. Stored sera were assayed for IGF-1, IGFBP-3, and GH by an automated chemiluminescent assay system (IMMULITE 2000, Diagnostic Products Corp., Los Angeles, Calif, USA). Serum nitric oxide measurement was performed using the Griess method for detection of nitrite levels [12].
###end p 10
###begin p 11
###xml 178 180 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U-</italic>
###xml 188 190 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P-</italic>
Statistical assessments were carried out with SPSS 10.0 packet program. All data were given as mean +/- standard deviation (SD). The results were analyzed using the Mann-Whitney U-test. A P-value of less than .05 was considered statistically significant.
###end p 11
###begin title 12
3. Results
###end title 12
###begin p 13
###xml 275 276 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 372 379 366 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
There were 25 patients (20 males, 5 females) in the PD group with a mean age of 67.9 +/- 9.4 years, and 25 healthy subjects (20 males, 5 females) in the control group with a mean age of 64.3 +/- 8 years. Age and sex distributions of patients and control groups were similar (P > .05). The mean Hoehn and Yahr stage was 3, and the duration of PD was 4.9 +/- 3.1 years (see Table 1). NO, IGF-1, and IGFBP-3 levels in serum of PD patients showed no correlation with the duration and severity of the disease (measured by the Hoehn and Yahr staging scale).
###end p 13
###begin p 14
###xml 50 52 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 127 129 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 137 143 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P:.011</italic>
###xml 281 282 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 295 302 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 250 257 <span type="species:ncbi:9606">patient</span>
The NO level of patients in PD group (2.3 +/- 0.4 mumol/L) was significantly lower than that in the control group (2.8 +/- 0.6 mumol/L) (P:.011). However, there were no statistically significant differences in the GH, IGF-1, IGFBP-3 levels among the patient and the control group (P > .05) (see Table 2).
###end p 14
###begin title 15
4. Discussion
###end title 15
###begin p 16
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 816 817 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 513 521 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Mitochondria are critical regulators of cell death and have been implicated as an important player in the death of dopaminergic neurons in PD. NO has been suggested to contribute, via impairment of mitochondrial function, to the neurodegenerative process [1, 3, 4]. It has previously been shown that formation of NO can be regulated via the GH-IGF-1 system, and this system may prevent the NO-mediated neuronal damage. But, the cellular mechanism for this regulation is unknown [9]. We found that the NO level of patients in the PD group was significantly lower than that in controls. Although statistically not significant, IGF-1 levels were mildly elevated in the patients with PD. These changes may be considered to reflect local adaptive and protective responses to an underlying pathological derangement [3, 5, 9, 13].
###end p 16
###begin p 17
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 986 987 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
The excess of NO could contribute to the formation of free radicals that could be involved in the death of dopaminergic neurons, leading to the development of PD symptoms [4]. Studies on nitrite and nitrate measurements in the cerebrospinal fluid (CSF) of PD patients have been contradictory, as there was no change [14-16], increase [17, 18], or decrease [19, 20]. On the other hand, some studies showed that CSF and plasma nitrate levels did not correlate with age at onset, duration, scores of the unified Parkinson's disease rating scales, and Hoehn and Yahr staging in the patients group [15, 16]. NO-mediated neurotoxic and neuroprotective effects seem to be dependent on its oxidative/reductive status, and the exact contribution to neurodegeneration is still not completely understood. An involvement of NO in the protective effect may occur via adaptive mechanisms. Therefore, the excessive NO synthesized in the course of adaptation is stored against the detrimental effects [4-6, 13]. We found that the nitric oxide level of patients in the PD group was significantly reduced than that in controls. The possible explanations for these low levels may be a defective NO-dependent adaptation mechanism or the exhaustion of NO storage in the course of PD. However, we found no significant correlation between these levels and the duration of disease and Hoehn and Yahr staging.
###end p 17
###begin p 18
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1188 1189 1188 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 578 583 <span type="species:ncbi:9606">human</span>
###xml 956 963 <span type="species:ncbi:9606">patient</span>
Growth hormone exerts much of its biological activity by stimulating the production of IGF-1, which is synthesized in nearly every tissue including the central nervous system and bounds to IGFBP-3. The GH-IGF-1 axis activity is reduced with age. Various studies showed that declining levels of serum IGF-1 contribute to age-associated brain impairments and neurodegenerative diseases such as PD and Alzheimer's [9, 21]. Also, IGF-I has recently been found of potential therapeutically use in different neurodegenerative conditions. Substantia nigra is one of the regions in the human brain, where a considerable density of IGF-1 receptors is evident. IGF-1 increases the survival of neurons in the brain stem and rescues embryonic DA neurons from programmed cell death [9, 22, 23]. It is found that serum IGF-1 levels are variable in the different diseases [9]. There were no statistically significant differences in the IGF-1 and IGFBP-3 levels among our patient and control groups. After a pathological condition develops, IGF-1 levels increase to protect affected neurons and to adapt to an underlying pathological process. This mechanism may explain the mildly elevated IGF-1 levels [9].
###end p 18
###begin p 19
###xml 36 43 <span type="species:ncbi:9606">patient</span>
###xml 161 168 <span type="species:ncbi:9606">patient</span>
Our study has some limitations; our patient group is rather small and had a male predominance. The results of this preliminary study must be confirmed in larger patient groups with different age and sex distributions.
###end p 19
###begin p 20
###xml 215 223 <span type="species:ncbi:9606">patients</span>
As a conclusion, there are few data about the role of NO on IGF-1, IGFBP-3 gene expression, and serum levels in PD. In this preliminary study, we found that there were low NO and mildly elevated IGF-1 levels in the patients. The results may be associated with adaptation or protective mechanisms in the neurodegenerative diseases process such as PD. Further studies should be carried out to confirm these results.
###end p 20
###begin article-title 21
Expanding insights of mitochondrial dysfunction in Parkinson's disease
###end article-title 21
###begin article-title 22
Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC): implications for Parkinson's disease
###end article-title 22
###begin article-title 23
Neurodegeneration or neuroprotection: the pivotal role of astrocytes
###end article-title 23
###begin article-title 24
Nitric oxide synthase regulation and diversity: implications in Parkinson's disease
###end article-title 24
###begin article-title 25
Nitric oxide: NO apoptosis or turning it ON?
###end article-title 25
###begin article-title 26
Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide
###end article-title 26
###begin article-title 27
Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS
###end article-title 27
###begin article-title 28
Neurodegeneration is associated to changes in serum insulin-like growth factors
###end article-title 28
###begin article-title 29
Role of insulin-like growth factor I signaling in neurodegenerative diseases
###end article-title 29
###begin article-title 30
###xml 92 97 <span type="species:ncbi:9606">human</span>
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease
###end article-title 30
###begin article-title 31
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Movement</italic>
###xml 113 121 113 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Movement</italic>
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. The Movement Disorder Society Task Force on rating scales for Parkinson's disease
###end article-title 31
###begin article-title 32
Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method
###end article-title 32
###begin article-title 33
Role of nitric oxide in adaptation to hypoxia and adaptive defense
###end article-title 33
###begin article-title 34
A marker of oxyradical-mediated DNA damage. (8-hydroxy- 2'deoxyguanosine) is increased in nigro striatum of Parkinson's disease brain
###end article-title 34
###begin article-title 35
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Cerebrospinal fluid nitrate levels in patients with Parkinson's disease
###end article-title 35
###begin article-title 36
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease
###end article-title 36
###begin article-title 37
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease
###end article-title 37
###begin article-title 38
Increased cerebrospinal fluid concentration of nitrite ire Parkinson's disease
###end article-title 38
###begin article-title 39
###xml 117 125 <span type="species:ncbi:9606">patients</span>
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients
###end article-title 39
###begin article-title 40
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Significantly reduced salivary nitric oxide synthesis in patients with Parkinson's disease
###end article-title 40
###begin article-title 41
The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease
###end article-title 41
###begin article-title 42
###xml 116 120 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats
###end article-title 42
###begin article-title 43
###xml 83 87 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
N-terminal tripeptide of IGF-I improves functional deficits after 6-OHDA lesion in rats
###end article-title 43
###begin p 44
###xml 38 46 <span type="species:ncbi:9606">patients</span>
 Age, sex, and clinic features of the patients with PD and healthy controls.
###end p 44
###begin p 45
###xml 111 119 <span type="species:ncbi:9606">patients</span>
 Nitric oxide, growth hormone, insulin-like growth factor-1, and insulin-like growth factor BP-3 levels of the patients with PD and healthy controls.
###end p 45
###begin p 46
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3 45 3 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">:.011, P:.52, P:.087, P:.19, respectively.</italic>
 *P:.011, P:.52, P:.087, P:.19, respectively.
###end p 46

